CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

CASI Pharmaceuticals Stock Performance

Shares of NASDAQ:CASI opened at $2.35 on Thursday. CASI Pharmaceuticals has a twelve month low of $2.05 and a twelve month high of $7.67. The firm has a market cap of $36.40 million, a PE ratio of -1.05 and a beta of 0.62. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.32 and a current ratio of 3.20. The business has a fifty day moving average of $3.11 and a 200-day moving average of $5.11.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC raised its stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 10.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,800 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Renaissance Technologies LLC owned 0.30% of CASI Pharmaceuticals worth $224,000 as of its most recent filing with the Securities and Exchange Commission. 22.23% of the stock is owned by hedge funds and other institutional investors.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.